Holen Sie sich die Stockscreener-App
21.94
6.12%
-1.43
Handel nachbörslich:
21.94
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results - Yahoo Finance
Alumis (NASDAQ:ALMS) Shares Down 4.1%Here's What Happened - marketbeat.com
Why Alumis Inc. Stock Is Dropping After Good News - TipRanks
Why is Alumis stock falling Monday? - MSN
10 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans - Yahoo Finance
Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib - Yahoo Finance
Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions - stocktitan.net
Foresite funds realign Alumis (ALMS) stakes via in-kind distributions - stocktitan.net
Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions - stocktitan.net
Tananbaum-led funds update Alumis (ALMS) ownership and 13D stake - stocktitan.net
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans - Sahm
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Why Alumis Inc. Shares Are Suddenly Surging - TipRanks
HC Wainwright Brokers Raise Earnings Estimates for Alumis - marketbeat.com
Alumis (NASDAQ:ALMS) Trading 12.1% Higher Following Analyst Upgrade - marketbeat.com
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST) - The Globe and Mail
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases - BioSpace
FY2027 Earnings Estimate for Alumis Issued By HC Wainwright - marketbeat.com
Alumis Furthers Its Case In TYK2 Race With Phase III Envudeucitinib Data - Citeline News & Insights
Oppenheimer Raises Price Target for ALMS, Maintains Outperform R - gurufocus.com
Alumis (ALMS): HC Wainwright & Co. Lowers Price Target, Maintains Buy Rating | ALMS Stock News - GuruFocus
Alumis (ALMS) Maintains "Buy" Rating and Price Target by Chardan Capital | ALMS Stock News - gurufocus.com
Alumis price target raised to $55 from $50 at Oppenheimer - TipRanks
Why Is Alumis Stock Falling Monday?Alumis (NASDAQ:ALMS) - Benzinga
Alumis (NASDAQ:ALMS) Trading Down 11.5% on Analyst Downgrade - marketbeat.com
Leerink reiterates Alumis stock rating on consistent trial data - Investing.com UK
US Stocks Recap: Is Alumis Incs growth already priced inTrade Exit Report & Verified Short-Term Plans - baoquankhu1.vn
Leerink reiterates Alumis stock rating on consistent trial data By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Alumis stock after trial data By Investing.com - Investing.com South Africa
Raymond James reiterates Strong Buy on Alumis stock after trial data - Investing.com India
Alumis (NASDAQ:ALMS) Given New $55.00 Price Target at Oppenheimer - marketbeat.com
Guggenheim reiterates Alumis stock rating on psoriasis trial data By Investing.com - Investing.com South Africa
Baird reiterates Alumis stock rating on Phase 3 data strength - Investing.com
Guggenheim reiterates Alumis stock rating on psoriasis trial data - Investing.com
Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Envudeucitinib Shows Early, Robust Skin Clearance and Quality of Life Improvements in Phase 3 Plaque Psoriasis Trials by Alumis Inc. 123 - minichart.com.sg
Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating - marketscreener.com
Alumis stock price target lowered to $25 by H.C. Wainwright on competitive pressures - Investing.com India
Stifel reiterates Alumis stock Buy rating after psoriasis data By Investing.com - Investing.com Canada
Chardan Capital Reiterates "Buy" Rating for Alumis (NASDAQ:ALMS) - marketbeat.com
Stifel reiterates Alumis stock Buy rating after psoriasis data - Investing.com
HC Wainwright Cuts Alumis (NASDAQ:ALMS) Price Target to $25.00 - MarketBeat
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib - TipRanks
Alumis Inc. Soars On Breakthrough Psoriasis Drug Update - TipRanks
Alumis: Envudeucitinib Shows Robust PASI 90/100 Responses and QoL Gains in Phase 3 ONWARD Trials - TradingView
Phase 3 win positions Alumis (NASDAQ: ALMS) psoriasis pill for 2026 NDA - stocktitan.net
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout - MarketBeat
Alumis (ALMS) Confronts Potential Regulatory Reassessment with NDA Submission Expected in Second Half of 2026 - Bitget
A Look At Alumis (ALMS) Valuation After ONWARD Phase 3 Psoriasis Data And FDA Filing Plans - simplywall.st
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):